VBL’s Thyroid Cancer Drug Clears Phase 2 (VBLT)

Share it with your friends Like

Thanks! Share it with your friends!


VBL’s Thyroid Cancer Drug Clears Phase 2 (VBLT)
“We are encouraged to see dose-dependent responses
and an overall survival benefit with VB-111 monotherapy, in thyroid cancer patients with end-stage disease whose tumors had not responded to multiple lines of therapies, including kinase inhibitors,” said Dr. Dror Harats, CEO of Vascular Biogenics.
The high-dose patient group also reported a decline in tumor measurement for seven out of 16 patients after a single
dose of VB-111, while the low dose patient group had one out of 11 patients achieving a fall in tumor measurement.
The drug is also in Phase 3 trial comparing a combination of VB-111
and Roche AG’s (RHHBY) Avastin to Avastin alone for treating patients with recurrent glioblastoma, and another phase 3 study for ovarian cancer is in the making.
Eight out of 17 (47%) patients in the VB-111 therapeutic-dose cohort achieved PFS-6, while four out of 12 (25%) patients
in the sub-therapeutic cohort achieved PFS-6, indicating both the cohorts hit the primary end point of the trial.
Vascular Biogenics Ltd. (VBLT) reported additional positive results for its thyroid cancer drug VB-111 (ofranergene obadenovec) from a Phase 2 trial.
The recent data builds upon previously reported data from the trial in 2015, and the overall survival results reported last year.


Write a comment